Next Article in Journal
A Pilot Study Investigating the Role of Gender in the Intergenerational Relationships between Gene Expression, Chronic Pain, and Adverse Childhood Experiences in a Clinical Sample of Youth with Chronic Pain
Previous Article in Journal
Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
Previous Article in Special Issue
New Aspects of the Epigenetics of Pancreatic Carcinogenesis
Open AccessReview

Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update

1
Department of Gastrointestinal Surgery, Aalborg University Hospital, 9000 Aalborg, Denmark
2
Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark
*
Author to whom correspondence should be addressed.
Academic Editors: Martin E. Fernandez-Zapico and Christopher Pin
Received: 15 March 2021 / Revised: 5 April 2021 / Accepted: 6 April 2021 / Published: 9 April 2021
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)
Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed. View Full-Text
Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma; epigenetic; DNA methylation; diagnostic biomarker; prognostic biomarker; cell-free DNA pancreatic cancer; pancreatic ductal adenocarcinoma; epigenetic; DNA methylation; diagnostic biomarker; prognostic biomarker; cell-free DNA
MDPI and ACS Style

Henriksen, S.D.; Thorlacius-Ussing, O. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update. Epigenomes 2021, 5, 8. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020008

AMA Style

Henriksen SD, Thorlacius-Ussing O. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update. Epigenomes. 2021; 5(2):8. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020008

Chicago/Turabian Style

Henriksen, Stine D.; Thorlacius-Ussing, Ole. 2021. "Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update" Epigenomes 5, no. 2: 8. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020008

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop